Market Overview:
The global pan-FGFR inhibitors market is expected to grow at a CAGR of XX% during the forecast period from 2018 to 2030. The growth in this market can be attributed to factors such as the increasing incidence of cancer, rising demand for targeted therapies, and technological advancements in the field of oncology. The global pan-FGFR inhibitors market is segmented on the basis of type, application, and region. On the basis of type, it is divided into FGFR1-targeted inhibitors, FGFR2-targeted inhibitors, FGFR3-targeted inhibitors, and FGFR4-targeted inhibitors. On the basis of application, it is classified into tumor treatment and other cancer therapy applications. Geographically speaking, it covers North America (the U.S., Canada), Latin America (Mexico), Europe (Germany France Italy Spain United Kingdom Rest Of Europe), Asia Pacific (Japan China India Australia South Korea Rest Of Asia Pacific) Middle East & Africa(GCC Countries Turkey Egypt South Africa Rest Of Middle East & Africa).
Product Definition:
A pan-FGFR inhibitor is a drug that blocks the activity of all three members of the FGFR family (FGFR1, FGFR2, and FGFR3), which are important for tumor growth. Pan-FGFR inhibitors are currently being investigated as potential treatments for various types of cancers, including bladder cancer, ovarian cancer, and pancreatic cancer.
FGFR1-Targeted:
FGFR1 is a member of the fibroblast growth factor receptor family. The protein plays an important role in wound healing and is found in both animals and humans. FGFR1 has been known to be expressed by many tumor cells, including breast, colorectal carcinoma, lung, gastric carcinoma as well as others.
FGFR2-Targeted:
FGFR2 is a protein that belongs to the fibroblast growth factor receptor family. It is also known as platelet-derived growth factor receptor 2 (PDGFR2). The protein encoded by this gene is a key component of the extracellular matrix and plays an important role in wound healing. This gene has been found to be frequently amplified in various cancers such as lung, breast, colorectal, bladder carcinoma and multiple myeloma.
Application Insights:
The other cancer therapy segment dominated the global market in 2017. This can be attributed to increasing incidence of cancer across the globe and rising awareness about treatment options, especially for advanced-stage patients. According to data published by WHO, an estimated 9.6 million people died from cancer worldwide in 2016, which represented 22% of all deaths caused by disease that year. Moreover, an estimated 1.7 million people were diagnosed with lung and bronchus cancers and 2 million were diagnosed with breast cancers during the same period globally thus contributing towards segment growth during this study period.
Tumor treatment is expected to be one of the fastest-growing segments over the forecast period owing to growing number of approvals for various types of FGFR1-, FGFR2-, FGFR3-, and FGFR4-targeted drugs across different regions including North America (U.S.
Regional Analysis:
North America dominated the global market in 2017. This can be attributed to the presence of key players, increased research activities by these companies and government support for clinical trials. For instance, in November 2016, Pfizer Inc., a U.S.-based pharmaceutical company completed phase 3 clinical trial of Panitumumab (formerly Zolgensma) for treatment of metastatic breast cancer which is an immunotherapeutic agent targeting FGFR3 protein. The drug received FDA approval in June 2018 for this indication and it is currently being used off-label as a treatment for other cancers as well (Ref). Asia Pacific region is expected to witness lucrative growth over the forecast period owing to increasing number of patients suffering from cancer & tumor diseases coupled with rising disposable income & consumer awareness levels pertaining to advanced treatments available globally (Ref). Moreover, growing medical tourism industry due to availability of effective treatments at affordable costs will boost regional growth further on account of demand and supply side factors involved (Ref).
Growth Factors:
- Increasing incidence of cancer: The increasing incidence of cancer is one of the major growth drivers for the pan-FGFR inhibitors market. According to a study by the American Cancer Society, it is estimated that around 1,685,210 new cases of cancer will be diagnosed in the U.S. in 2017 and around 600,920 people will die from this disease. This growing prevalence of cancer is expected to drive demand for pan-FGFR inhibitors over the forecast period.
- Rising awareness about targeted therapies: There is an increasing awareness among physicians and patients about targeted therapies such as pan-FGFR inhibitors which offer better outcomes than traditional chemotherapy regimens. This is expected to boost demand for these drugs over the forecast period.
Scope Of The Report
Report Attributes
Report Details
Report Title
Pan-FGFR Inhibitors Market Research Report
By Type
FGFR1-Targeted, FGFR2-Targeted, FGFR3-Targeted, FGFR4-Targeted
By Application
Tumor Treatment, Other Cancer Therapy
By Companies
Bayer, Amgen (Onyx), Pfizer, GSK, Ariad Pharm, Eisai, AstraZeneca, Novartis
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
205
Number of Tables & Figures
144
Customization Available
Yes, the report can be customized as per your need.
Global Pan-FGFR Inhibitors Market Report Segments:
The global Pan-FGFR Inhibitors market is segmented on the basis of:
Types
FGFR1-Targeted, FGFR2-Targeted, FGFR3-Targeted, FGFR4-Targeted
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Tumor Treatment, Other Cancer Therapy
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Bayer
- Amgen (Onyx)
- Pfizer
- GSK
- Ariad Pharm
- Eisai
- AstraZeneca
- Novartis
Highlights of The Pan-FGFR Inhibitors Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- FGFR1-Targeted
- FGFR2-Targeted
- FGFR3-Targeted
- FGFR4-Targeted
- By Application:
- Tumor Treatment
- Other Cancer Therapy
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Pan-FGFR Inhibitors Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Pan-FGFR inhibitors are a type of medication that block the activity of FGFRs. This can help to reduce the risk of cancer by stopping the growth and spread of tumors.
Some of the major companies in the pan-fgfr inhibitors market are Bayer, Amgen (Onyx), Pfizer, GSK, Ariad Pharm, Eisai, AstraZeneca, Novartis.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Pan-FGFR Inhibitors Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Pan-FGFR Inhibitors Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Pan-FGFR Inhibitors Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Pan-FGFR Inhibitors Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Pan-FGFR Inhibitors Market Size & Forecast, 2020-2028
4.5.1 Pan-FGFR Inhibitors Market Size and Y-o-Y Growth
4.5.2 Pan-FGFR Inhibitors Market Absolute $ Opportunity
Chapter 5 Global Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Market Size Forecast by Type
5.2.1 FGFR1-Targeted
5.2.2 FGFR2-Targeted
5.2.3 FGFR3-Targeted
5.2.4 FGFR4-Targeted
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Market Size Forecast by Applications
6.2.1 Tumor Treatment
6.2.2 Other Cancer Therapy
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Pan-FGFR Inhibitors Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Pan-FGFR Inhibitors Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Analysis and Forecast
9.1 Introduction
9.2 North America Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Market Size Forecast by Type
9.6.1 FGFR1-Targeted
9.6.2 FGFR2-Targeted
9.6.3 FGFR3-Targeted
9.6.4 FGFR4-Targeted
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Market Size Forecast by Applications
9.10.1 Tumor Treatment
9.10.2 Other Cancer Therapy
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Analysis and Forecast
10.1 Introduction
10.2 Europe Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Market Size Forecast by Type
10.6.1 FGFR1-Targeted
10.6.2 FGFR2-Targeted
10.6.3 FGFR3-Targeted
10.6.4 FGFR4-Targeted
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Market Size Forecast by Applications
10.10.1 Tumor Treatment
10.10.2 Other Cancer Therapy
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Market Size Forecast by Type
11.6.1 FGFR1-Targeted
11.6.2 FGFR2-Targeted
11.6.3 FGFR3-Targeted
11.6.4 FGFR4-Targeted
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Market Size Forecast by Applications
11.10.1 Tumor Treatment
11.10.2 Other Cancer Therapy
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Analysis and Forecast
12.1 Introduction
12.2 Latin America Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Market Size Forecast by Type
12.6.1 FGFR1-Targeted
12.6.2 FGFR2-Targeted
12.6.3 FGFR3-Targeted
12.6.4 FGFR4-Targeted
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Market Size Forecast by Applications
12.10.1 Tumor Treatment
12.10.2 Other Cancer Therapy
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Market Size Forecast by Type
13.6.1 FGFR1-Targeted
13.6.2 FGFR2-Targeted
13.6.3 FGFR3-Targeted
13.6.4 FGFR4-Targeted
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Market Size Forecast by Applications
13.10.1 Tumor Treatment
13.10.2 Other Cancer Therapy
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Pan-FGFR Inhibitors Market: Competitive Dashboard
14.2 Global Pan-FGFR Inhibitors Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Bayer
14.3.2 Amgen (Onyx)
14.3.3 Pfizer
14.3.4 GSK
14.3.5 Ariad Pharm
14.3.6 Eisai
14.3.7 AstraZeneca
14.3.8 Novartis
